Related references
Note: Only part of the references are listed.Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda et al.
CANCER DISCOVERY (2018)
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
Luca Mologni et al.
NEOPLASIA (2018)
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
Sara Redaelli et al.
CANCER RESEARCH (2018)
Intermittent vemurafenib therapy in malignant melanoma
Nicolai Treiber et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2017)
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP
Tomohide Tamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Xiangjun Kong et al.
NATURE (2017)
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
M. Ceccon et al.
ONCOGENE (2016)
Mitochondrial Stat3, the Need for Design Thinking
Rui Yang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin et al.
CANCER RESEARCH (2015)
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Nitesh Sharma et al.
MOLECULAR CANCER (2015)
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni et al.
ONCOTARGET (2015)
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
M. Ceccon et al.
MOLECULAR CANCER RESEARCH (2015)
Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
A. Koop et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
Yohei Funakoshi et al.
INVESTIGATIONAL NEW DRUGS (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
Sara Redaelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Conversion from the oncogene addiction to drug addiction by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
Kenichi Suda et al.
LUNG CANCER (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Direct control of mitochondrial function by mTOR
Arvind Ramanathan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERK1/2 MAP kinases in cell survival and apoptosis
Zhimin Lu et al.
IUBMB LIFE (2006)
Prolonged activation of ERK1, 2 induces FADD-independent caspase 8 activation and cell death
S Cagnol et al.
APOPTOSIS (2006)
Restoration of sensitivity to STI571 in ST1571-resistant chronic myeloid leukemia cells
AJ Tipping et al.
BLOOD (2001)
Share Paper
